Ultrasound in medicine & biology · 2025
Local Delivery of miR-27a* Using Ultrasound-Targeted Microbubble Cavitation Inhibits Squamous Cell Carcinoma Growth.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chari Nikhil S, Chen Cheng, Ramasamy Thiruganesh, Chen Xucai, Wadhwa Geetika, Paranjape Anurag N, Lai Stephen Y, Villanueva Flordeliza S
Аннотация
OBJECTIVE: Ultrasound-targeted microbubble (MB) cavitation (UTMC) is an image-guided therapeutic oligonucleotide delivery platform utilizing intravenously injected gas-filled ultrasound contrast agents, which carry the therapeutic on the MB shell. During transit of MBs in the microcirculation of target tissue, ultrasound causes MB oscillation, facilitating endocytosis-independent payload uptake within insonified cells. Here, we tested the hypothesis that UTMC-mediated miR-27a* delivery will reduce tumor growth rate and result in accumulation of miR-27a* within tumor cells and the tumor microenvironment.
METHODS: We used UTMC to deliver miR-27a* to SCC-VII cells in vitro and in SCC-VII mouse tumor models. Pulsed ultrasound was delivered during intravenous (i.v.) infusion of lipid encapsulated MBs loading either miR-27a* (miR-27a*-MB + UTMC) or negative control MBs (Con-miR-MB + UTMC).
RESULTS: miR-27a*-MB+UTMC treatment significantly reduced SCC-VII cell viability in vitro and SCC-VII tumor growth in vivo compared to negative controls (Con-miR-MB+UTMC, i.v. miR-27a* or no treatment). Forty-eight hours following treatment, protein expression of direct miR-27a* targets (epidermal growth factor receptor [EGFR], NUP62 and ΔNP63α) was significantly reduced in miR-27a*-MB + UTMC vs i.v. miR-27a* or Con-miR-MB + UTMC. Further, whereas i.v. miR-27a* did not decrease tumor expression of these proteins vs. non-treated tumors, miR-27a*-MB + UTMC significantly reduced tumor expression of EGFR, NUP62 and ΔNP63α by 50%-75%, compared to non-treated tumors.
CONCLUSION: These data substantiate the utility of UTMC for non-invasive delivery of oligonucleotide payloads to extravascular target sites and suggests the therapeutic potential of miR-27a* for the treatment of head and neck squamous cell carcinoma.
METHODS: We used UTMC to deliver miR-27a* to SCC-VII cells in vitro and in SCC-VII mouse tumor models. Pulsed ultrasound was delivered during intravenous (i.v.) infusion of lipid encapsulated MBs loading either miR-27a* (miR-27a*-MB + UTMC) or negative control MBs (Con-miR-MB + UTMC).
RESULTS: miR-27a*-MB+UTMC treatment significantly reduced SCC-VII cell viability in vitro and SCC-VII tumor growth in vivo compared to negative controls (Con-miR-MB+UTMC, i.v. miR-27a* or no treatment). Forty-eight hours following treatment, protein expression of direct miR-27a* targets (epidermal growth factor receptor [EGFR], NUP62 and ΔNP63α) was significantly reduced in miR-27a*-MB + UTMC vs i.v. miR-27a* or Con-miR-MB + UTMC. Further, whereas i.v. miR-27a* did not decrease tumor expression of these proteins vs. non-treated tumors, miR-27a*-MB + UTMC significantly reduced tumor expression of EGFR, NUP62 and ΔNP63α by 50%-75%, compared to non-treated tumors.
CONCLUSION: These data substantiate the utility of UTMC for non-invasive delivery of oligonucleotide payloads to extravascular target sites and suggests the therapeutic potential of miR-27a* for the treatment of head and neck squamous cell carcinoma.